Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol loxenatide + levonorgestrel-releasing intrauterine system
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Peptides
- Administration
- Subcutaneous, Intrauterine
01
Overview
Polyethylene glycol loxenatide + levonorgestrel-releasing intrauterine system (LNG-IUS) is a combination therapy being investigated for the treatment of endometrial atypical hyperplasia (AEH) in obese women. Polyethylene glycol loxenatide (PEX168) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes. It works by improving insulin sensitivity, inhibiting appetite, and reducing systemic inflammation, which are critical factors in obese patients with AEH. The LNG-IUS is a hormonal device that provides local sustained release of levonorgestrel, a progestogen, directly to the endometrium to counteract the effects of estrogen and promote regression of hyperplasia. This combination approach aims to improve complete response rates and preserve fertility by addressing both the local endometrial pathology and the underlying metabolic drivers of the disease.
- Brand names
- FulaimeiMirena
- Other names
- PEG-loxenatide + LNG-IUSPolyethylene Glycol Loxenatide Plus LNG-IUS
02
Targets
GLP1R (GLP-1R)PR (Progesterone receptor)
Beyond the preview
Go deeper on polyethylene glycol loxenatide + levonorgestrel-releasing intrauterine system.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol loxenatide + levonorgestrel-releasing intrauterine system.